Lynparza on cusp of EU approval for advanced ovarian cancer

Lynparza received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment of germline BRCA-mutated HER2-negative metastatic ovarian cancer. A positive opinion leads to recommendation for approval.